Latest News

​

Practitioners who sell supplements need to be aware that health and medical claims made in nutritional marketing can attract unwanted attention from the US Food and Drug Administration.

Tune in to hear Asa Waldstein of the Supplement Advisory Group, a boutique group focusing on marketing risk analysis and practical marketing solutions for the web and social media, discuss the latest need-to-know regulatory information impacting the cognition, adaptogen, and nootropic space.

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Brands need to ensure regulatory responsibilities are accounted for at the start of a contract manufacturing partnership.

In this interview, Professor Ted Dinan, Medical Director at Atlantia Clinical Trials, and Asa Waldstein, Principal at Supplement Advisory Group, discuss Atlantia’s expertise in clinical trials for CBD

Asa Waldstein, principal at Supplement Advisory Group, advises companies on how to navigate murky waters in today's marketplace.

Former FDA officials and lawyers who advise clients on FDA regulations weigh in on a recent batch of warning letters targeting new dietary ingredients marketed in supplements.

​

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Presentation

Asa and other industry leaders interviewed

Asa Waldstein's content is mentioned in this newsletter.

This edition talks about labeling essentials and best practices.

Asa Waldstein quoted

Asa Waldstein and two top advertising attorneys share their tips and best practices for marketing stress supplements.
🔷Stress-free rules Ivan Wasserman, Amin Talati Wasserman, LLP
🔷Pooja's do's and don'ts Pooja Nair
🔷Asa's helpful hints Supplement Advisory Group

Asa Waldstein, Principal, Supplement Advisory Group, discussed the most recent info on FDA and FTC’s thinking regarding immune support in Communicating in-store and online—where are we now? “FDA is going back many years and citing multi-year-old social media posts in warning letters,” he shared. “One cited a social media post from 2014, and they treat those the same way as new posts. Hashtags are also claims. ‘Liking’ a post is a claim. Replying to or reposting a customer comment on social media, that’s a claim. All marketing is considered ‘labeling’.” That includes, he said, product reviews and testimonials; infographics; citing studies; blogs; and more.

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

This edition talks about manufacturing essentials and reasons to think twice when building an overly robust Quality Management System (QMS).

Asa and other industry leaders interviewed